Search company, investor...


Founded Year



Unattributed VC - II | Alive

Total Raised


Last Raised

$40M | 15 yrs ago

About Minrad

Minrad, Inc. is a manufacturer of generic inhalation anesthetics

Headquarters Location

50 Cobham Drive

Orchard Park, New York, 14127,

United States


Missing: Minrad's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Minrad's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Minrad Patents

Minrad has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Projective geometry, Accelerator physics, Triangle geometry, Optical devices, Euclidean plane geometry


Application Date


Grant Date



Related Topics

Projective geometry, Accelerator physics, Triangle geometry, Optical devices, Euclidean plane geometry



Latest Minrad News

As stock market plunges, a star money manager says the Fed is making a mistake by focusing on rates. Here’s what Scott Minerd says it should do instead.

Jan 24, 2022

Liquidity can be better managed by pulling back the supply, which the market has enjoyed. “Changes in the money supply are a powerful driver of economic output, asset prices, and inflation,” writes Minrad. “Interest rates are a byproduct of monetary liquidity, economic output and inflationary expectations. Short-term market rates can be manipulated through changes in the money stock,” he wrote. Minrad says one of the negative implications for the size of the Fed’s balance sheet was the reverse repo rate, a major artery of global financial markets. The Fed’s reverse repo program allows eligible firms like banks and money-market mutual-funds to park large amounts of cash at the Fed overnight, at a time when short term funding rates Have fallen to next to nothing, and it’s hard to find a home where the cash is. The program had almost no participants at the beginning of April of last year, and since the beginning of the pandemic in the spring of 2020, but in May 2021 there was an increase in demand. “That facility now has a daily volume of more than $1.5 trillion,” Minrad writes. “Any program to raise rates would require the Fed to increase the interest rate paid on RRP operations by the amount of the overnight target rate increase,” he said. “In essence, the Fed will set an artificial rate that is not determined by market forces,” Minrad said. In other words, free-flowing liquidity has created artificial levels for rates that are not driven by market forces. Minrad says that without the ability to accurately gauge market conditions through mechanisms such as the RRP, the Fed is essentially flying blind. “Without market forces, the Fed would have no ability to identify what the real demand for money would be if interest rates could float freely and thus use a signaling mechanism to indicate the true equilibrium rate of interest. builds,” he writes. Minrad said raising rates dramatically would destabilize the financial system and jailed him against suggestions that the Fed should focus on a “shock and awe” strategy by raising rates by 50 basis points instead of 25 basis points. in which the market is determined. Economists are, in fact, expecting the Fed to reduce its asset purchase program, end that program in early March, triple interest rates and close its balance sheet. Is the market crashing? No. Here’s what’s happening to stocks, bonds as Fed aims to end easy money days, say analysts Mined will encourage the Fed to focus on its balance sheet. He says controlling the growth of the money supply may be more effective in resetting policy and may be a better strategy for the central bank than raising interest rates. Minrad’s comments come as the S&P 500 Index SPX, -2.72%

Minrad Frequently Asked Questions (FAQ)

  • When was Minrad founded?

    Minrad was founded in 2005.

  • Where is Minrad's headquarters?

    Minrad's headquarters is located at 50 Cobham Drive, Orchard Park.

  • What is Minrad's latest funding round?

    Minrad's latest funding round is Unattributed VC - II.

  • How much did Minrad raise?

    Minrad raised a total of $57.15M.

  • Who are the investors of Minrad?

    Investors of Minrad include UBS, Perseus, Aisling Capital, Highbridge Capital Management, Cowen and 11 more.

  • Who are Minrad's competitors?

    Competitors of Minrad include Spectrum Medical, Lucina Health, Magnetecs, CardiAQ Valve Technologies, Aragon Surgical and 11 more.

Compare Minrad to Competitors

Spectrum Medical

Spectrum Medical is a manufacturer of oxygen saturation devices that are used in ECMO and Open Heart Surgery. Spectrum Medical supplies Clinical Information Solutions that include Medical Device Connectivity Technologies, Electronic Medical Record Systems, Telemedicine Capabilities and Compliance and Patient Safety Solutions. Spectrum Medical also supplies Non-invasive Diagnostics Systems for extracorporeal procedures. The company was founded in 2007 and is based in Gloucester, England.


CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.

Clearflow Logo

Clearflow develops a clearable catheter systems to solve the clinical problems caused by internally obstructed medical tubes. The company's platform of catheter systems enable caregivers to actively clear internal obstructions to ensure these critical tubes perform optimally. The company's lead product is the PleuraFlow Active Clearance Technology (ACT) System for chest tubes. By preventing chest tube failure, PleuraFlow enables caregivers to manage postoperative bleeding more safely, reliably, and efficiently.

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Ost Medical

The company are a enterprise recognized in the enteral products industry as a manufacturer of high quality, yet cost-effective devices. The company supply products to domestic and international customers. The company also are a contract manufacturer focused on the development and production of equipment for the medical and life sciences industries. The company's organization is composed of individuals with years of industry experience. OST Medical has a strong commitment to the company's customers and the company are confident in the company's ability to meet customer expectations in quality, price and delivery.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.